

Gerhard Gross, Director, Early Drug Developability, Janssen Research and Development

Gerhard has a B.Sc. degree in Physics and Chemistry, and received his M.Sc. in Physics and Chemistry (1980) and Ph.D. in Organic Chemistry (1983) from the University of Marburg where he studied the generation of reactive molecules through flash vacuum pyrolysis. As a postdoc he worked with Prof. Michl in Utah, USA on multiple silicon bonds. In the past years Gerhard was holding several senior positions in pharmaceutical industry among them Department head ADME in Novartis and head DvDMPK AP, in AstraZeneca and Lundbeck. After working as head of drug metabolism department in Lundbeck, he joined Janssen in 2013 as director in Early Drug Developability. Gerhard has extensive experience in the area of drug development and drug discovery especially ADME. He was setting up ADMET screening and profiling in Novartis and Aventis. He has been a key player in the development and registration of numerous drugs during his work for Novartis e.g. Glivec, Everolimus, Exjade, Myfortic, Rasilez, Zelmac and Zoledronate. He holds several patents for Glivec, Exjade and Rasilez. In AstraZeneca he was establishing a transporter group, an outsourcing group and a biomarker group in Alderley Park in 2006. In 2008 he was leading a cross functional team within AstraZeneca to elaborate an internal strategy for the new FDA MIST guideline. He was also responsible to develop the global ADME strategy in 2010. Gerhard worked in Lundbeck from 2010 to 2013 as head of drug metabolism; he was responsible for the registration of Nalmefene (DMPK part) and he was also establishing the Lundbeck strategy on transporters and reactive metabolites. Gerhard joined Janssen in March 2013 as head of early drug developability. He is author of 28 publications and gave more than 14 lectures at scientific congresses including running a series of lectures on metabolites and toxicity at the University of Bern, Switzerland. Currently he also works as lecturer of Copenhagen University and in the advisory board of Entomopharm.